Lantern Pharma announced the appointment of David Margrave as Chief Financial Officer and Kishor Gopaldas Bhatia as Chief Scientific Officer.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.28 USD | +7.90% | +1.45% | +46.73% |
May. 09 | Transcript : Lantern Pharma Inc., Q1 2024 Earnings Call, May 09, 2024 | |
May. 09 | Lantern Pharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+46.73% | 62.62M | |
+44.48% | 54.04B | |
+43.57% | 41.96B | |
-0.86% | 41.92B | |
-7.59% | 28.35B | |
+12.30% | 26.35B | |
-21.83% | 19B | |
+7.15% | 13B | |
+29.40% | 12.28B | |
+25.15% | 12.19B |
- Stock Market
- Equities
- LTRN Stock
- News Lantern Pharma Inc.
- Lantern Pharma Inc. Announces Executive Changes